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Coronavirus disease of 2019 (COVID-19) is a zoonotic disease caused by a new severe acute respiratory
syndrome (SARS-CoV-2) which has quickly resulted in a pandemic. Recent anti-COVID-19 drug
discoveries are leaning towards repurposing phytochemicals which have been previously reported for
SARS and MERS-CoV outbreaks. However, they have been either virtually screened or tested so far
against mono targets and the potent derivatives of virtually sorted lead molecules remain elusive. We
aimed to identify the phytochemicals having potentials to inhibit SARS CoV-2 infection via multiple
targets. The selected 132 phytochemicals were virtually screened using a structure based in silico
technique against main protease (Mpro) which is a potential target of SARS CoV-2. Six compounds were
selected based on the LibDock scores and further subjected to induced fit docking using the CDOCKER
module of DS. Two compounds namely cinnamtannin-B and gallocatechin gallate were identified as top
HITS against main protease (Mpro). Based on the Lipinski rule of five (L-ROF) and synthetic feasibility,
gallocatechin gallate was taken for our further studies. Six analogues of gallocatechin gallate were
screened against the next important targets such as RNA-dependent RNA polymerase (RdRp),
angiotensin converting enzyme-2 (ACE2), transmembrane protease serine -2 (TMPRSS2) and interleukin-
6 (IL-6) along with main protease (Mpro). Our molecular docking results reveal that a gallocatechin
analogue (GC-2) namely (2R,3R)-2-(3,4-dihydroxyphenyl)chroman-3-yl-3,4,5-trihydroxy benzoate has
shown potential to inhibit multiple targets of SARS CoV-2. Further, the molecular dynamics study was
carried out to ascertain the stability of the GC-2 and RdRp complex.The novel coronavirus disease of 2019 (COVID-19) is an infec-
tious disease and responsible for the 2019–2020 viral pneu-
monia outbreaks. The World Health Organization (WHO)
declared that the outbreak of COVID-19 is pandemic on the 22nd
of April 2020. Sadly, this pandemic is still enduring and hence
there is an urge to nd novel prophylactic or therapeutic
measures to combat the COVID-19 pandemic.1–4 However, toJSS College of Pharmacy, JSS Academy of
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tion (ESI) available. See DOI:
the Royal Society of Chemistrydate there have been no specic therapeutics proven to eradi-
cate COVID-19, which warrants multi-focused and multi-
targeted strategies like, drug candidates having potentials to
act on multiple antiviral targets and concurrently boost the host
immune system.5,6 The US FDA has launched the Coronavirus
Treatment Acceleration Program (CTAP) and specic guidance
on COVID-19 clinical trials. Additionally, the FDA has issued
emergency use authorizations for some drugs, for example,
chloroquine, hydroxychloroquine, and Remdesivir. However,
recent clinical trials investigating this drug concluded that the
treatment was not signicantly correlated to intubation risk or
mortality by multiple analyses. Remdesivir, a nucleotide pro-
drug, inhibits viral RNA-dependent RNA polymerase and has
been reported to have in vitro activity against SARS-CoV-2.7
There are now seven known coronaviruses that cause disease in
humans to include, HCoV-229E, HCoV-OC43, HCoV-NL63,
HCoV-HKU1, severe acute respiratory syndrome coronavirus
(SARS-CoV) and Middle East respiratory virus coronavirus
(MERS-CoV), and now SARS-CoV-2.8 The rst four CoVs cause
























































































View Article Onlinecoronaviruses are highly pathogenic, leading to communicable
outbreaks causing fatal respiratory diseases. Coronaviruses
have the largest genomes among all known RNA viruses,
ranging from 26 to 32 kb in length, which encode structural and
nonstructural proteins. Several structural components of the
coronavirus family viruses have been described as bio targets
for drug discovery. These targets are related to viral nucleic
acids, enzymes, spike glycoprotein, and envelope (membrane,
nucleocapsid, and accessory proteins).7 A massive effort has
been undertaken by the international scientic community to
obtain structural information about complexes between SARS-
CoV-2 targets and different types of inhibitors, providing
information to use ligand-based (LB) and structure-based (SB)
approaches to drug repurposing. The drugs such as amodia-
quine and darunavir have also been repurposed for Covid
therapy through in silico tools.9 There are also reports for the
organic compounds such as alpha ketoamides and 3-alkynyl
substituted 2-chloroquinoxaline frame work as lead compounds
for Covid therapy.10,11 The present work evaluated the drugg-
ability of the SARS-CoV-2 main protease (SARS-CoV-2 Mpro) as
a potential target for the approved drug for the treatment of
COVID-19 as it plays a crucial role in the cleavage of viral pol-
yproteins involved in transcription and replication. Many
research teams have exploited the major protease (Mpro) of
SARS-CoV-2, also named chymotrypsin-like protease (3CLpr),12
as a potential drug target to ght COVID-19. Sequence align-
ment revealed that the SARS-CoV-2Mpro shares a 96% similarity
to that of SARS-CoV-1. This enzyme is reported to be inhibited
by several classes of compounds, some of which exhibit anti-
CoV activities in vitro, in vivo, and even in nonrandomized
trials (such as lopinavir).7 RNA-dependent RNA polymerase
(RdRp) is a key enzyme essential for the viral replication of
SARS-CoV-2.13 Due to their crucial roles, these viral proteins are
considered imperative targets for developing antiviral
compounds against COVID-19. The SARS-CoV-2 genome
encodes more than 20 proteins, which include the main
protease (Mpro), a 3C-like protease (3CLP) that shares 96.1%
similarity with 3CLP of SARS-CoV.7 Mpro, a homodimeric
cysteine protease, plays an important role in SARS virus repli-
cation and transcription. When the mRNA of the virus is
translated polyproteins, Mpro is rst auto-cleaved to become
a mature enzyme, which in turn cleaves all of the 11 remaining
downstream nonstructural proteins of the polyproteins to
polypeptides, which are required for the replication process of
the virus. The prime anti-COVID-19 target proposed is the main
protease (Mpro; also known as 3 chymotrypsin like protease or
3CLpro), which is regarded as responsible for the cleavage of
viral peptides into functional units for virus replication and
packaging within the host cells. Likewise, the enzyme RNA
dependent RNA polymerase (RdRp) responsible for viral RNA
synthesis is also considered a druggable target to inhibit SARS-
CoV-2. Conceivably, the interaction of viral spike proteins with
its receptor, angiotensin-converting enzyme-2 (ACE2) on host
cells, and subsequent viral endocytosis into the cells, may also
are regarded as a viable drug target. Similarly, the enzyme
transmembrane protease serine-2 (TMPRSS2) produced by the
host cells plays an important role in proteolytic processing of S13052 | RSC Adv., 2021, 11, 13051–13060protein priming to the receptor ACE2 binding in humans and
has gained attention.14–18 Whilst, these targets have been
currently investigated extensively with numerous drugs and
biologicals, the poly targeting approaches such as the leads
having the potential to act on synergistic pathways concurrently
by which SARS-CoV-2 infection is inhibited in the host cells. The
cytokines, including interleukins, play a vital role in regulating
host cell immune responses. Upon the SARS-CoV infection,
a rapid and severe immune reaction occurs, and this triggers
the synthesis and release of relatively higher levels of interleu-
kins into the bloodstream. Consequently, the raise of pro-
inammatory cytokines leads to severe respiratory organ
failure, high fever, and other associated diseases.19 Owing to
these reasons, we hypothesize that the drug candidates having
the potential to elicit anti-viral effects on multiple targets along
with benecial immunomodulatory effects in host cells, organs
or systems would enable novel therapeutic leads to combat the
COVID-19 pandemic. Thus, our study intended to search for the
leads having the potential to act on multi druggable targets of
COVID-19 along with benecial immunomodulatory effects.
Whilst, the drug discovery and developmental research has
undergone signicant modernization in recent decades, the
three fourth of humankind still depend largely on the bioactive
from natural sources.20 The plants and their parts have been
serving human mankind as sources of herbal medicine since
ancient times. They possess a variety of constituents, such as
avonoids, alkaloids, glucosides, and polyphenolic
compounds. These phytochemicals offer a wide range of ther-
apeutic properties and novel scaffolds to design new drugs.21,22
Of note, several phytochemicals have been reported benecial
in preventing or treating zoonotic viral diseases including SARS
and MERS-CoV. The plant constituents having bi, mono
&heterocyclic rings specially bioavonoids adapt to the geom-
etry of the 3CLpro substrate site and have prominent interac-
tions with the surrounding amino acid residues.23 This is
further substantiated by the ndings of cannabisin A and iso-
acetoside as potential 3CLpro inhibitors by Free Energy Pertur-
bation studies.24 In regards, we have collated the potent
phytochemicals which have been previously reported to inhibit
SARS and MERS-CoV. This study aims to narrow and sort the
selective 132 phytomolecules (ESI Table 1†) based on its binding
affinities and interactions on major druggable target of COVID-
19 using in silico computational tools. Besides, the analogues of
the sorted lead molecule were prepared and examined for its
molecular docking, ADMET, and molecular dynamics.
Materials and methods
Docking soware and ligand library
LIBDOCK and CDOCKER modules of Discovery Studio 3.5
soware (DS3.5, Accelrys, Inc., San Diego, CA, USA) were
utilized for virtual screening and ligand binding analysis of
inhibitors. A library consisting of 132 plants secondary metab-
olites already reported for SARS-CoV (2003) and MERS-CoV
(2012), and other viruses aer sessional outbreaks caused by
dengue and inuenza virus was generated (ESI Table 1†). All
phytochemicals were screened for Mpro and the top hit and its© 2021 The Author(s). Published by the Royal Society of Chemistry





























































































View Article Onlineanalogs were further docked with the proteins Mpros, RdRp,
ACE-2, TMPRSS2, and IL-6. The binding energies and the
interactions were compared with the known inhibitors of the
selected proteins Lopinavir, Favipiravir, Ramipril, camostat,
and tartaric acid respectively. A detailed workow is depicted in
Fig. 1a.2 Cinnamtannin B1 184.88
3 Dieckol 175.51
4 Gallocatechin gallate 173.33
5 Broussoavan A 172.76
6 Hygromycin B 172.23
7 Epi-gallocatechin gallate 167.03
8 Ginkgetin 165.38
9 Amentoavone 165.32
10 Epi-catechin gallate 164.68
11 Remdesivir 177.63Structure-based virtual screening using LIBDOCK
LIBDOCK is a rigid-based docking program. It calculates hot-
spots for the protein using a grid placed into the binding site
and using polar and polar probes (San Diego, CA, USA). Then
the hotspots are further used to align the ligands to form
favorable interaction. Aer minimized, all the ligand poses are
ranked based on the ligands score. The 1.7A crystal structure of
CoV main proteases (Mpros) in complex with N3 a mechanism-
based inhibitor (PDB ID: 7BQY) were downloaded from the
protein data bank (PDB) and imported to the working envi-
ronment of LIBDOCK. The protein was prepared by removing
crystal water and other heteroatoms (except N3), followed by the
addition of hydrogen, protonation, ionization, and energy
minimization. The CHARMm (Cambridge, MA, USA)25 force
eld and the Smart minimizer algorithm were applied for
energy minimization. The minimization performed 2000 steps
with an RMS gradient tolerance of 0.1, and the nal RMS
gradient was 0.09463. The prepared protein was used to dene
the binding site from the “Edit binding site” option on the
receptor–ligand interaction toolbar. Using the bound ligands
(N3) binding positions, the active sites for docking were
generated. Virtual screening was carried out by docking all the
prepared ligands at the dened active site using LIBDOCK.Fig. 1 (a) Experimental workflow (b) Ramachandran plot of Mpro.
© 2021 The Author(s). Published by the Royal Society of ChemistryBased on the LIBDOCK score, all the docked poses were ranked
and grouped by name. All compounds were ranked according to
their LIBDOCK score.
The molecular docking (CDOCKER) module of Discovery
Studio was used for the molecular docking study. CDOCKER is
an implementation of a CHARMm based docking tool. The
receptor is held rigid while the ligands were allowed to ex
during the docking process. For each complex pose, the
CHARMm energy (interaction energy plus ligand strain) and the
interaction energy, which indicate ligand binding affinity was
calculated. The crystal structures of Mpros (PDB ID: 7BQY, 1.7A),
RdRp (PDB ID: 6WTC, 1.85 A), ACE-2 (PDB ID: 6ACK, 4.5 A),
























































































View Article OnlineA)26 were obtained from the protein data bank. The crystal water
molecules were generally removed in rigid and semi-exible
docking process27,28 since the xed water molecules might
affect the formation of the receptor–ligand complex. The water
molecules were removed, and hydrogen atoms were added to
the protein. The structure was completed by modelling the
missing loops. The missing atoms were inserted by standard-
izing the names of the atom. The titratable residues were
protonated by pKa prediction. The potential energy van der
Waals energy, Electrostatic energy, and RMS gradient of the
complexes were checked before and aer protein minimization.
Finally, the hydrogen receptors were merged to the target
receptor molecule using discovery studio 4.1 clients.29 The
prepared proteins were validated through a Ramachandran plot
(Fig. 1b).25 The selected plant constituents were generated and
optimized using ChemSketch soware. All the tautomer's and
isomers of the ligand were regarded and of the ligands pos-
sessing the lowest energy had been approved for docking.
The CHARMm force eld was used for energy mini-
misation. The binding site spheres of all the proteins were
dened as the regions that come within a radius of 15 A from
the geometric centroid of the native ligands. The binding site
spheres of all the proteins were dened by structural align-
ment. During the docking process, the ligands were allowed to
bind to the residues within the binding site spheres. Aer
being extracted from the binding site, the native ligands were
re-docked into the crystal structure of all proteins. The RMSD
between the docked pose and the crystal structure of the
complex was less than 1 A, indicating the CDOCKER module
was highly reliable for reproducing the experimentally
observed binding mode of all proteins. The structures of
identied hits were prepared and docked into respective
proteins. Different poses for each test molecule were gener-
ated and analyzed based on CDOCKER interaction energy. The
designed compounds were minimized and used as input
ligands in the protocol explorer of CDOCKER. The molecular
dynamic protocol was used to generate various conformations
for ligand and the initially generated structures were rened
using a simulated annealing protocol. CDOCKER energies
were calculated for each compound. The various binding
interactions between the ligand and protein were predicted.
The protocol uses a CHARMm-based molecular dynamics
(MD) scheme to dock ligands into a receptor binding site.
Random ligand conformations are generated using high-
temperature MD. The conformations are then translated into
the binding site. Candidate poses are then created using
random rigid-body rotations followed by simulated annealing.
A nal minimization is then used to rene the ligand poses.
The CDOCKER energy as an estimation of molecular complex
binding affinity was used in this study.Molecular dynamics
The molecular dynamic (MD) simulation was conducted to
study the stability of the ligand–target complex.30 The simula-
tion is set to constant number (N), volume (V), and temperature
(T) (NVT) ensemble with temperature varying from 300 K, run:13054 | RSC Adv., 2021, 11, 13051–1306080 ns, time step: 0.002, and quality threshold (QT) (the
temperature response set enforce constant temperature in
a molecular dynamics simulation) is set to 0.2 (Fig. 1c). It took
12.55 h to complete the simulation. The ligand–target
complexes were then subjected to molecular dynamics simula-
tion using NAMD with the following parameters; minimization-
2000 steps; annealing-144 000 steps; equilibration & MD-
500 000 steps; NVT temperature 27 C/300 K; NPT pressure-1
atm and simulation time-80 ns.
The highly constructive conformation, pose and favorable
bonded complexes form receptor ligand interaction was used an
input to study molecular dynamics simulation (MD) for the
compound GC-6. The CHARMm (Chemistry at Harvard Macro-
molecular Mechanics) force eld were applied to each complex
system followed by two step minimization of 500 cycles with
steep descent (SD) and conjugate gradient (CG) to eliminate
possible steric strain. The relaxed and energy minimized
complex were then subjected to three steps of dynamics and
simulation. Initially, receptor–ligand complex was gradually
simulated and heated from a temperature of 50 K followed by its
ramping to 300 K and then equilibrated by 100 steps at 310 K for
even distribution of atoms in a system (protein–ligand) to be
constrained. Finally, production of CHARMm simulation was
performed for 80 ns and conformations were allowed to save for
every 2 ps. Furthermore, the Spherical Cutoff method of elec-
trostatics was implemented to study the all-non-bonded energy.
In order to x hydrogen bonding during simulation leap frog
verlet a dynamics integrator was introduced with SHAKE
constraint. Equilibration of the complex system was monitored
by convergence in terms of the H-bond, root-mean-square
uctuation (RMSF) and the RMSD (root-mean-squared
deviations).
Results
Virtual screening of phytochemicals database against CoV
main proteases (Mpros)
The prime target, coronavirus main protease (Mpros), which is
a chief culprit enzyme, guides in mediating the transcription
and replication process of the virus31 has been assigned for our
study. There are30 000 nucleotides have compressed together
in the virus genome of novel COVID-19, its gene may perhaps
encode with two polyproteins namely, pp1a and pp1ab, which
are desirable for viral replication and transcription.32,33 The
main Proteolytic enzyme, Mpros, through the Proteolytic process
could release the polypeptides from these polyproteins. Besides,
this Mpro enzyme is the main protein in the viral cell life cycle
together with the absence of closely related homolog's of
human protein, recognizes the Mpros as a promising target for
the anti-viral drug discovery. Therefore, the inhibition of Mpro
may perhaps block the biosynthesis of the viral polyprotein,
resulting in viral death. To identify new compounds that could
potentially inhibit Mpros through binding to the ligand binding
pocket, virtual screening was carried out using the LibDock
module of DS.
The top 10 phytochemicals which have higher binding affin-
ities with Mpro relative to all docked molecules are listed in Table© 2021 The Author(s). Published by the Royal Society of Chemistry
Table 2 CDOCKER energies of selected phyto-constituents
S. no. Molecule
-CDOCKER interaction
energy (kcal mol1) Pose
1 Gallocatechin gallate 43.69 1
2 Cinnamtannin B1 34.54 1
3 Dieckol 29.90 1
4 Broussoavan A 4.85 1
5 Isotheaavin 30-gallate 22.85 1
6 Hygromycin B 9.57 1
























































































View Article Online1. The binding affinities obtained for phytochemicals were
compared with a conventional Mpro inhibitor, Remdesivir which
is also extensively used for the treatment of COVID-19. The
results reveal that the phytochemicals namely isotheaavin 30-
gallate, dieckol, gallocatechin gallate, broussoavan A, and
hygromycin B have shown LibDock scores similar to Remdesivir
(LibDock score: 177.63). Of note, the LibDock score of cinnam-
tannin B1 was higher than the score obtained for Remdesivir.Ligand binding analysis
To study ligand binding mechanisms, the top six ranked
compounds isotheaavin 30-gallate, dieckol, gallocatechin
gallate, broussoavan A, hygromycin B, and cinnamtannin B1
were docked into the 3D structure of (Mpros) by using theFig. 2 (a–c) the inter-molecular interaction of the predicted binding mo
to Mpros. (d–f) Bar diagrams depicting the favourable interactions of the
and (f) Remdesivir.
© 2021 The Author(s). Published by the Royal Society of ChemistryCDOCKER module of DS. The CDOCKER energy as an estima-
tion of molecular complex binding affinity was used in this
study. As shown in Table 2, the CDOCKER energy of galloca-
techin gallate and cinnamtannin B1 were lower than the refer-
ence Remdesivir, indicating that these two compounds elicit
a higher binding affinity with Mpros. The energy of the other
compound dieckol is close to Remdesivir. However, the inter-
action energy of compounds broussoavan, isotheaavin 30-
gallate, and hygromycin were not signicant when compared to
the reference Remdesivir. The increased binding energies of
gallocatechin gallate and cinnamtannin B1 were further sup-
ported by the comparative analysis of receptor–ligand interac-
tions with the active amino acid residues of Mpros. The major
non-bonded interactions such as hydrophilic, hydrophobic, and
pi–pi interactions of these two compounds were investigated
and compared with the standard Remdesivir (Fig. 2a–c ESI
Tables 2 and 3†).
The results showed that both gallocatechin gallate and cin-
namtannin B1 formed eight and seven pairs of hydrogen bonds
withMpros, respectively whereas the drug Remdesivir has shown
ve pairs of hydrogen bonds only. The additional hydrogen
bonds formed may be the reason for the increased binding
affinity of these two compounds than Remdesivir. Both of the
compounds formed three pair Pi–Pi interactions with Mpros, by
the centroid of the benzene ring of methionine and the centroid
of the benzene ring of gallocatechin gallate and cinnamtannindes of (a) gallocatechin gallate; (b) cinnamtannin B1 and (c) Remdesivir
residues of Mpros towards (d) gallocatechin gallate (e) cinnamtannin B1
RSC Adv., 2021, 11, 13051–13060 | 13055











GA 0.25 460.4 8 11 2
CT 3.3 864.8 14 18 3
Table 4 Substitution pattern of designed gallocatechin analogues of
finding effective viral inhibitors
Compound R1 R2 R3 R4 R5
GC-1 OH OH OH OH OH
GC-2 OH OH H H H
GC-3 OH H OH OH OH
GC-4 OH H H H H
GC-5 OH H OH H H
GC-6 H H OH OH OH
GC-7 H H H H H
Table 5 CDOCKER interaction energies of designed compounds
























































































View Article Onlinerespectively. The interactions of the amino acid residues are
depicted in (Fig. 2d–f). These results indicated that galloca-
techin gallate and cinnamtannin B1 probably bind to Mpros
with similar or even better affinity than Remdesivir.
Design of gallocatechin analogs Lipinski rule of ve (L-ROF)
is an important parameter for oral drug candidates. When we
analyzed the L-ROF of two compounds gallocatechin gallate and
cinnamtannin, violations of the gallocatechin were 3 and 2
respectively (Table 3).
It is a well-known fact that beyond the violation of 2 is
questionable. Based on these results, we decided to proceed
with gallocatechin further. Chemical modication of naturally
derived compounds may be required to increase the potency.
For the drug discovery process, beginning with the under-
standing of the structural conformity (i.e. structure including
potential isomers) of the naturally derived compound(s) can
timelines and greatly increase the chance. Working on this
principle we designed six analogs of gallocatechin (Fig. 3a and
b). To alter the hydrogen bond donor/acceptor and to increase
the hydrophobicity, the OH groups of ring A and C of galloca-
techin are removed in a sequential manner to derive the analogs
(Table 4).
The designed analogs were further docked with the proteins
Mpros, RdRp, ACE-2, TMPRSS2, and IL-6. The binding energies
and the interactions were compared with the known inhibitors
of the selected proteins lopinavir, favipiravir, Ramipril, camo-
stat, and tartaric acid respectively. As shown in Table 5 the
CDOCKER energies of designed analogs were compared with
known inhibitors. The selected compounds have shown the
least CDOCKER energy towards ACE-2, IL-6, and RdRp among
the ve targets compared to the known standards (>2.11781,
19.1244, and 3263 kcal mol1) respectively. Against COVID
main protease, and transmembrane protease serine-2 proteins,
the CDOCKER energy of tested compounds were not signicant.
The energies were bigger than the standard lopinavirFig. 3 (a and b) Gallocatechin gallate scaffold.
13056 | RSC Adv., 2021, 11, 13051–13060(<51.2735 kcal mol1), (<48.1854). However, the compounds
GC-3 and GC-6 have shown the CDOCKER energies which are
nearing the standard. Interestingly, the CDOCKER energies of
tested compounds were lower towards the proteins ACE-2, IL-6,
and RdRp than the reference compounds Ramipril, tartaric
acid, and favipiravir, respectively. These results indicating the
compounds may possess COVID-19 combating activity through
the inhibition of these proteins. Among all, compound GC-3
and compound GC-6 shows signicant activity towards all the
enzymes. However, a further detailed in vitro study is needed to
prove this concept.Molecular dynamics study
In computational drug discovery, MD is a technique that sheds
light on the allosteric binding site of the protein, and confor-
mation of the ligand–protein complex. Also, it can simulate the
conditions that are hard to perform in wet experiments. Herein,
compound GC-6 was subjected to MD simulations bound to the
SARS-CoV-2 RdRp. The initial conformations were acquired
from the molecular docking experiments by CDOCKER. It can
be seen from Fig. 4a that compound GC-6 retained its binding
affinity and was rmly bound to its respective binding site. The
RMSD curves of the receptor structures from each complex and
the potential energy proles of each complex are shown in
(Fig. 4b and c).Compound MPRO TMPRSS2 ACE-2 IL-6 RdRP
GC-1 41.61 36.07 30.40 31.69 42.11
GC-2 34.12 31.73 22.23 24.78 30.58
C-3 44.07 37.68 28.49 31.64 37.37
GC-4 35.24 32.41 22.25 28.53 33.80
GC-5 37.82 33.60 21.98 26.43 33.28
GC-6 40.60 37.83 25.43 31.54 43.09
GC-7 33.53 27.87 17.13 23.34 27.96
Lopinavir 49.42 — — — —
Ramipril — — 25.12 — —
Camostat — 54.24 — — —
Favipravir — — — — 22.57
Tartaric acid (co-crystal) — — — 17.61 —
© 2021 The Author(s). Published by the Royal Society of Chemistry
























































































View Article OnlineThe trajectories of complexes reached equilibrium aer 10
ns, RMSD, and the potential energy of the complexes gets
stabilized with time. The H-bond distances formed between GC-
6 and RdRp were within a range of around 3.0 and 2.3 A.








GC-6 9.2003 H 5948 OE 3340 GLU
H 5962 O 1702 ASP
H 5964 O 1702 ASP
H 5962 OD 2043 ASP
H 5966 OD 2043 ASP
© 2021 The Author(s). Published by the Royal Society of Chemistrywater molecules aer molecular dynamics simulation (Table 6).
These hydrogen bonds might contribute to the stability of the
complexes. The RMSD values of each receptor-ligand complex
were plotted to elucidate the effect of the compounds on the
structural stability and integrity. From this plot, 6WTC_GC-6ue (number) Chain (number) Type Score (%)
Distance
(A)
23 6WTC 3 H-donor 21.60 1.42
112 6WTC 2 H-donor 25.00 3.64
112 6WTC 2 H-donor 38.20 1.77
134 6WTC 2 H-donor 42.40 1.23
134 6WTC 2 H-donor 34.00 1.53
























































































View Article Onlineshowed sharp increase in RMSD up to 2 nano seconds. Later
6WTC_GC-6 deviations are optimized up to 80 nano seconds,
then it increase slightly to 0.75 A further the complex attained
equilibrium till the end of dynamics.
Considering all the evaluation indexes, the compound GC-6
might interact with RdRp steadily and have potential negative
modulator effects on RdRp.Discussion
One family of compounds that demonstrate antiviral activity
across several studies is the polyphenols. It was well known that
hydrophobicity plays a major role in predicting the binding
affinity towards SARS-CoV-1. Several natural sources from ora
and fauna have been tested in terms of their anti-SARS-CoV-1
activity and used as a scaffold in drug development since its
outbreak in 2003 (ESI Table 1). These natural metabolites
include avones, avonols, fatty acids, tannins, terpenes, and
alkaloids.
The diversity of these chemical classes is related to the
different mechanisms used by each phytochemicals class
capable to inhibit coronaviruses. Jo et al. (2019) stated that
SARS-CoV-1 inhibition requires chemical structures containing
a hydrophobic aromatic ring, hydroxyl groups, and carbohy-
drates moieties. Although not all of the anti-SARS-CoV-1
compounds (ESI Table 1†) present the aromatic ring, their
molecular structures have lipophilic and hydrophilic regions
and the ability to form multiple hydrogen bonds through
hydroxyl groups. It was well evidenced by our results that the
identied compound has hydrophobic and multiple hydroxyl
groups. Several investigations revealed the anti-SARS-CoV-2
activity of catechins or polyphenols through the inhibitory
potential of MProS alone, which have been highlighted by R.
Ghosh et al. recently. Although the importance of MProS has
been established as a prime target for COVID-19, there are
targets like RdRp and ACE-2. TMPRSS-2 and IL-6 have not been
explored yet. There were also limited studies of the polyphenols
and catechins against the mentioned targets. Poly targeting is
also a reasonable approach to avoid issues related to resistance
and toxicity.
Keeping all these views, we wanted to study the GC and its
analogs against these multiple targets. Interestingly, we
observed the best binding affinities of GC against the targets
RdRp, ACE-2, TMPRSS2, and IL. Though it is a potential HIT
against these multiple targets, it fails to satisfy L-ROF. L-ROF is
a very basic lter for oral drug candidates. In view of these, we
designed analogs of GC where the OH groups have been
modied (to satisfy HBD ¼ 5; HBA ¼ 10) and all were within the
range (0–1 violation) (Table 5). All the designed analogs (GC-2 to
GC-7) have shown a comparable binding affinity with GC itself;
however, the compound GC-6 was identied as the topmost
HIT. By considering binding energies, amino acid residues
interactions nod molecular dynamics studies, we propose the
following pharmacophoric query for having multitarget inhib-
itory potential of SARS-CoV-2. Ring aromatics >3; hydrogen
bond acceptors >8; hydrogen bond donors >5.13058 | RSC Adv., 2021, 11, 13051–13060Conclusion
The rapidly spreading outbreak of COVID-19 has challenged the
healthcare sector of the world in the last few months. Several
investigations have demonstrated that a variety of plant
secondary metabolites especially polyphenolic have been re-
ported for anti-SARS-CoV-1& 2 activities since 2002. However,
there is very little evidence as yet that these constituents work to
prevent or treat SARS-CoV-1& 2 in humans. Moreover, these
plant secondary metabolites inhibit anyone's target and not
much of their analogs have been reported so far against this
SARS CoV-2. To overcome the less efficacious/resistance prob-
lems of plant secondary metabolites against SARS CoV-2, we
aimed to identify any single molecule that can target all
important targets involved in SARS CoV-2. A systematic struc-
ture based in silico study was carried out to meet our objective. A
gallocatechin analog namely (2R,3R)-2-(3,4-dihydroxyphenyl)
chroman-3-yl-3,4,5-trihydroxy benzoate has been identied as
a multiple targeting inhibitor. Gallocatechin gallate, a catechin
and a constituent of green tea, is an epimer of epigallocatechin
gallate. There were strong evidences at in silico level for its effect
SARS CoV-2 therapy. An in silico molecular docking study with
SARS CoV-2 3CL protease showed that EGCG strongly interacted
with Mpro indicating that EGCG potentially inhibit SARS CoV-2.
3CL protease-cleavage of viral proteins by protease is a vital step
for viral replication.34–36
Further, it is supported by Minsu Jang et al., that EGCG
inhibits 3CL protease activity of SARS-CoV-2 in dose dependent
manner and the half inhibitory concentration (IC50) was 7.58 mg
ml1 examine the effect of EGCG on coronavirus. EGCG treat-
ment decreases 3CL-protease activity of HCoV-OC43 and HCoV-
229E. Moreover, EGCG treatment decreased HCoV-OC43-
induced cytotoxicity. Finally, they also found that EGCG treat-
ment decreased the levels of coronavirus RNA and protein in
infected cell media. These results indicate that EGCG inhibits
coronavirus replication.37,38 In another study, the polyphenol
EGCG exhibited signicant effect on various druggable targets
of SARS CoV-2. These results suggest the potential activity of tea
polyphenols in the treatment of COVID-19. The use of tea phyto
constituents over synthetic drugs is an exciting treatment
option since they are safer, and a higher dose is feasible.
However, the bulkiness of these polyphenols and violations of
Lipinski's rules could be hindrances in their development. Oral
bioavailability is a concern for these polyphenols for which to
overcome their derivatives are being developed. EGCG deriva-
tives are being tested for enhancement in physicochemical
properties and better efficacy. In line of these, we wanted to
explore the efficacy of gallocatechin gallate against various
druggable targets of SARS-CoV-2.39 However, further studies are
warranted for the validation of these compounds using in vitro
and in vivo models to pave a way for these compounds in anti-
COVID-19 drug discovery.
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